RecruitingNot ApplicableNCT06978777

Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity


Sponsor

University Hospital, Basel, Switzerland

Enrollment

12 participants

Start Date

Jan 21, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the study is to asses brown adipose tissue activity after a cold mild stimulus, preceded by 200mg caffeine or placebo administration.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria4

  • BMI 18.5 to 25 kg/m2
  • Able to give informed consent as documented by signature
  • Moderate caffeine consumption (1 to 3 cups of coffee per day)
  • Increase of EE in response to mild cold of ≥ 5% of REE

Exclusion Criteria16

  • Known hypersensitivity or allergy to caffeine
  • Concomitant medication other than prescription free analgesics (paracetamol and NSAID) and oral contraceptives
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cardiac arrhythmia, hypertension, diabetes mellitus, hyper- or hypothyroidism)
  • History of depressive disorder or anxiety disorder
  • Smoker / habitual tobacco use
  • Habitual excessive alcohol use
  • Regular consumption of caffeine containing energy drinks
  • Weight change of \>5% within 3 months prior to inclusion
  • Systolic blood pressure \>140 mmHg and/or diastolic blood pressure \> 95 mmHg.
  • Resting heart rate \>90 bpm
  • Hypersensitivity to cold (e.g. Raynaud syndrome)
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Enrolment of the investigator, his/her family members, employees, and other dependent persons
  • Enrolment into another study using ionizing radiation within the previous 12 months.
  • Pregnancy or lactation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCaffeine (200 mg)

single dose of 200mg caffeine orally in study visit A

DRUGPlacebo

single dose of 1 tablet Placebo in study visit B


Locations(1)

University Hospital Basel, Department of Endocrinology

Basel, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06978777


Related Trials